A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
Latest Information Update: 02 Aug 2023
At a glance
- Drugs Cannabidiol (Primary)
- Indications Prader-Willi syndrome
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc; Radius Pharmaceuticals
- 11 Nov 2020 Status changed from recruiting to discontinued.
- 27 Apr 2018 Status changed from not yet recruiting to recruiting, according to an INSYS Therapeutics media release.
- 02 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.